The reaction of aged carboplatin (reaction of carboplatin in 24 mM NaHCO 3 for 45 h, 37 o C, pH 8.6) with pBR322 DNA for 0 ≤ r ≤ 2.8, where r = [drug]/ [DNAbp], in 24 mM HEPES buffer, pH 7.4, for 24 h followed by agarose gel electrophoresis showed DNA mobility changes consistent with unwinding closed circular DNA. However, identical experiments conducted in a two buffer system, 24mM HEPES plus 24mM carbonate, showed no DNA mobility changes, indicating that carbonate blocks formation of the 1,2-intrastrand crosslink on DNA. Studies with aged carboplatin and with cisplatin carried out with 2.0 ≤ r ≤ 10.0 in the two buffer system show that some DNA binding and unwinding occurs for both drugs. Since carbonate inhibits the binding of aged carboplatin and cisplatin to DNA, carbonate present in the body likely modulates the reactivity of these drugs with a variety of biological targets including DNA.
INTRODUCTION
Platinum drugs have long been used in clinical cancer therapy. Since the serendipitous discovery of the antiproliferative properties of cisplatin, [cis-Pt(NH 3 ) 2 Cl 2 ], by Barnett Rosenberg over 30 years ago (1, 2) , this compound has been successfully used in the treatment of ovarian, testicular, and many other cancers (3) . However, the drug's severe side effects, often including kidney and nervous system toxicity, severe nausea, and high-frequency hearing loss (4), led the search for improved Pt 2+ anticancer compounds.
One of the second-generation drugs developed to ameliorate these shortcomings was carboplatin, [cis-Pt(NH 3 ) 2 (CBDCA-O,O')], where CBDCA is cyclobutane-1,1-dicarboxylate. Clinically, carboplatin is less oto-and nephrotoxic than cisplatin (3, 5) , and is useful against cisplatin-resistant malignancies (6) . Carboplatin's bidentate dicarboxylate chelate makes the drug much less reactive than cisplatin, which may partly explain the reduction in side effects seen in chemotherapy (7) . Electrophilic platinum compounds have been shown to bind DNA in the cell, forming mono-and bifunctional adducts (7) (8) (9) . It is generally thought that such DNA lesions induce apoptosis, destroying cancerous cells, though other mechanisms of action have been proposed (10) . Research has shown that cisplatin and carboplatin both interact with DNA in roughly the same manner.
Knox et. al. found in 1986 that, although carboplatin binds DNA at a much slower rate than cisplatin, both drugs form the same type of adduct on DNA (5) . Their results showed that roughly 100 times as much carboplatin as cisplatin is needed to achieve an equivalent amount of DNA binding, though smaller ratios have been reported (11) ; however, equal binding resulted in equal DNA lesions and cytotoxicity for the two drugs. Further research by Hongo et. al. supported the conclusion that the two drugs differ mainly in kinetics, and showed that both drugs preferentially target G,G sequences on DNA (6) .
Reports of carboplatin's extremely slow reaction with DNA belied the drug's effectiveness in clinical use, leading researchers to look for a possible mechanism of activation in vivo. Carboplatin had been shown to first bind DNA monofunctionally as a monoaquo species, with loss of the CBDCA ligand leading to formation of a bifunctional adduct (5) . However, the reaction of carboplatin with water proceeds extremely slowly (k 1 = 7.2 × 10 -7 s -1 ), indicating that aquation might not produce enough of the necessary ring-opened species in vivo to allow significant DNA binding (5) . Further, DNA-binding carboplatin species were most prevalent under highly basic conditions not seen in the human system (6) .
Though direct interaction between unmodified carboplatin and DNA had been suggested (7, 11) , investigation into activation mechanisms which could produce ring-opened carboplatin species in vivo began.
One proposed activating agent was carbonate, found in equilibrium with bicarbonate, carbonic acid, and aqueous carbon dioxide and present at high concentration (23.8mM) in the blood (12, 13) . Carbonate has been shown to play an important role in the cellular uptake and toxicity of Ti 4+ , Pb 2+ and Cd 2+ (14) (15) (16) , and carbonato complexes of Pd 2+ were shown to form via substitution by (19) . Further study has shown that Jurkat cells are able to defend against cisplatin attack via production of a drugmodifying extracellular substance (20) . (24) . It was also seen that Jurkat cells produce an unidentified extracellular substance which modifies carboplatin (25) , similar to the defense mechanism against cisplatin reported by Dabrowiak and coworkers (20) .
In this study, we sought to determine the effect of carbonate on the DNA binding of carbonate-activated carboplatin. We followed the carbonate aging procedure outlined by Di Pasqua (23, 24) , providing the full variety of carbonatocarboplatin species thought to develop under physiological conditions. By carrying out DNA binding in a carbonate-rich solution, we modeled the environment of cellular DNA in vivo. We used closed-circular plasmid DNA as our binding target, and measured the extent of binding through agarose gel electrophoresis, a benchmark technique in the study of platinum-DNA binding (5, 6, 9) . We found that physiologically-relevant concentrations of carbonate in the DNA environment prevented binding of carbonate-aged carboplatin.
We then broadened the conditions of the study, using higher molar ratios of both carbonate-aged carboplatin and cisplatin to determine whether carbonate changed the mode of DNA binding, the rate, or both. We found that carbonate's limiting effect on DNA binding could be overcome by high molar ratios of both drugs, indicating that the 1,2-intrastrand crosslink could still form in the presence of carbonate. These findings were published in 2008 (26) .
We then attempted to quantify the carbonate effect. We sought to determine, using mass spectrometry, the amount of platinum bound to DNA in the presence and absence of carbonate, in order to obtain a rate for platinum-DNA binding in a carbonate-rich environment. Several tries at measuring the binding using this technique proved inconclusive. Additionally, we did a preliminary study using ethanol precipitation to isolate platinated DNA for binding measurement, but this was also unsuccessful.
Despite these difficulties in gathering quantitative data, our findings indicate that carbonate greatly reduces the rate of DNA binding of both cisplatin and carbonate-activated carboplatin. We show how platinum drugs, specifically the modified species which may form in the blood, interact with DNA in an environment similar to that inside the cell, and how this differs from previous models. Since it is critically important to observe how these drugs react under conditions of human chemotherapy, our findings may help clarify carbonate's role in the activity of these platinum drugs. Form I DNA showed a gradual decrease in migration distances with increasing r, similar to the trend seen at low r-values in HEPES alone but much less pronounced. Form II migration seemed to increase slightly where 2.0 ≤ r ≤ 6.0, decreasing again for 6.5 ≤ r ≤ 10.0. Control experiments were performed under nitrogen, argon, and ambient air atmospheres. Various migration trends were seen, but the results could not be repeated and data from these experiments was discarded.
MATERIALS & METHODS

Materials
RESULTS
Carboplatin binding in HEPES:
Ethanol DNA precipitation: A standard ethanol precipitation protocol (27) was
performed to isolate platinated DNA after the 24 hour drug-DNA incubation step.
After multiple attempts, no DNA was isolated, and this technique was abandoned.
DISCUSSION & CONCLUSIONS
In this study we use agarose gel electrophoresis to examine the effects of carbonate-aged carboplatin and cisplatin on the electrophoretic mobility of pBR322 plasmid DNA when binding is carried out in carbonate media. Since this gel technique does not require any work-up of the metalated DNA prior to gel analysis, it is especially well suited for Pt-DNA binding studies involving carbonate buffer.
Our preliminary study, testing the DNA binding of carbonate-aged carboplatin at low r-values, showed distinct migration changes when reaction took place in HEPES buffer only. The initial decrease of Form I mobility, followed by co-migration with Form II, then increased mobility, corresponds with trends seen for both cisplatin (9, 21, 22) and carboplatin (5, 6) in previous gel electrophoresis studies. Using carbonate-activated carboplatin at low concentration, we were able to see migration patterns which were only observed using lengthy incubation times (6) or much higher drug concentrations (5) Our observations with carboplatin showed some key differences compared with earlier cisplatin studies. First, while the "coalescence point" (where Form I and Form II migrate to the same point on the gel) occurs at r = 1.4, this point does not seem to correspond to the migration for DNA with zero supercoiling (Form II when r = 0.0) as it did for Keck and Lippard (9) . Second, the staining intensity trends seen here differ from those found in cisplatin studies (21) . In our study, Form I intensity decreased with increasing drug concentration, opposite the published cisplatin trend. These observations may highlight differences between carboplatin and cisplatin DNA interactions.
When carbonate-activated carboplatin was reacted with DNA at low rvalues in carbonate media, there were no readily-apparent changes in migration indicative of drug binding. Form I DNA showed the same migration for all rvalues, while Form II migration increased a slight amount as r increased. This trend corresponds well with prior observations on the binding of cisplatin at similar r-values in carbonate media (21, 22) . From our observations, the 24 mM carbonate present in the reaction buffer was enough to prevent DNA binding of the drug. Here again, intensity decreased for Form I, counter to trends published for cisplatin studies.
Carbonate-aged carboplatin is known to contain carbonato/bicarbonato complexes (23) ; when the activated drug is added to a carbonate-free medium, these species lose CO 2 through mass action effects (28 species and concentrations. The system models the proposed in vivo activation mechanism from start to finish, operating on biochemical principles rather than operator input.
The system we have constructed carries out DNA binding under conditions identical to those of the human body in terms of carbonate concentration, H + ion concentration, and temperature. The carboplatin activation step preceding DNA binding strays from strict physiological conditions with significantly increased reaction times and carbonate concentrations; these conditions are employed to provide a surplus of the carbonate-modified species expected to form in the blood stream. Overall, our system establishes a model which is similar to the DNA binding environment of both cisplatin and carboplatin, providing a relevant system to carry out studies on these two drugs.
In conclusion, our findings show that DNA binding of cisplatin and carbonate-activated carboplatin is affected by the presence of carbonate buffer at physiologically relevant concentrations. In particular, our high r-value studies
show that the formation of the conventional 1,2-intrastrand crosslink is negatively influenced by the presence of carbonate for both drugs. Since carbonato/bicarbonate complexes can form by attack from carbonate, the presence of this material in the biological system may control the concentration of biologically reactive metal aquo species of cisplatin and carboplatin and their reactivity with targets including DNA. Clearly, elucidating the complex equilibria associated with these important reactions requires further investigation.
This work demonstrating the role of carbonate in the mechanism of action of platinum anticancer drugs shows the importance of studying drug activity under biologically relevant conditions, and it is our hope that such investigations will continue in the field of anticancer drug research.
